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A retrospective study on the effects of
illness severity and atrial fibrillation on
outcomes in the intensive care unit
There are many ways in which AF can cause adverse events,
including haemodynamic compromise, impairment of left
ventricular function and thromboembolic complications.13
While several studies have shown AF in the critically ill to be
associated with increased severity of illness, longer length of
hospital and critical care unit stay and higher mortality,4–9
another paper did not confirm these findings.1 In this study,
Annane et al. found that the effect on mortality was lost after
adjusting for confounders.1 It is therefore unclear whether
arrhythmia is simply a marker of illness severity5,7–9 or sep-
sis,6,10,11,14 or directly contributes to poorer outcomes.
The aim of this study was to look at the incidence of AF
in our patient population using prospectively collected data
on admission characteristics, severity of illness scores and
outcomes. We also wanted to determine whether the char-
acteristics of intensive care unit (ICU) patients who devel-
oped AF in association with a critical illness were different
to those of ICU patients who were diagnosed with AF in the
community. In addition, we aimed to provide further insight
into the relationship between illness severity and AF, using
C-reactive protein (CRP) as a marker of inflammation.
Troponin levels were not routinely monitored in all of our
patients during the time period of this study, but would have
been taken in the presence of an arrhythmia. To exclude the
obvious bias, troponin levels were not analysed in this study.
METHODS
This study used prospectively collected and stored data from
an ICU in a large tertiary-referral university hospital in
Glasgow, Scotland. These data are used for clinical care,
local and national audits, and are incorporated into elec-
tronic case records. Only data used and stored as part of
routine care were used in this study. The unit predominant-
ly admits patients requiring mechanical ventilation and
multiple organ support. Cardiothoracic and cardiology
patients are not admitted to our ICU. This is a general ICU
and therefore the case mix is derived from the general hos-
pital population, along with tertiary-care cases.
Consecutive patients admitted between April 2006 and
September 2009 were included in this study. This period
was chosen because of the introduction of the electronic
record system (IntelliVue Clinical Information Portfolio,
Philips Medical Systems, Amsterdam, The Netherlands).
Data collected for all patients included age, sex, Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score, predicted hospital mortality, actual ICU and hospi-
tal mortality, length of ICU stay and highest CRP level.
In our system, patients’ vital signs are automatically
entered into an electronic case record. These parameters, and
the cardiac rhythm displayed on the continuous electrocar-
diogram (ECG) monitor, are then confirmed by the bedside
Introduction: Atrial fibrillation (AF) is common in patients in
the intensive care unit (ICU) and has been associated with
worse outcomes. However, it is unclear whether AF itself adds
to the risk of death or is merely a marker of illness severity.
We aimed to record the incidence and outcomes of all patients
with different categories of AF and determine whether AF was
an independent predictor of death.
Methods: This retrospective cohort study was undertaken in
the ICU of a tertiary-referral university hospital. Category of AF,
sex, C-reactive protein (CRP) level, APACHE II score, predicted
hospital mortality and survival outcomes were analysed from
1084 records. Percentages, medians and interquartile ranges
were used to describe the sample. Chi-square test and the
non-parametric Mann–Whitney U test were used, as appropri-
ate, for statistical analysis. Logistic regression analyses were
performed to evaluate the association of AF with death in the
ICU adjusting for age, sex, CRP level and APACHE II score.
Results: Overall, 13.6% of patients developed new-onset AF
during their critical illness, while 4.3% had a pre-existing his-
tory. The hospital mortality rate was higher in those with AF
compared with those without (47.9% vs. 30.9%, p<0.001) and
higher in those with newly diagnosed AF compared with those
with a prior history (53.1% vs. 31.9%, p=0.012). CRP levels
were higher in those with AF (p<0.001) compared with those
without and higher in those with newly diagnosed AF com-
pared with those with a prior history (p=0.012). On multivari-
ate logistic regression analysis, only the APACHE II score was
found to be an independent predictor of death.
Conclusion: Despite the higher mortality rate in patients
with AF, the APACHE II score was the only independent pre-
dictor of death within the ICU. Prospective studies are
required to explore the apparently reduced risk of dying
among those with a prior history of AF.
Atrial fibrillation (AF) is the most common arrhyth-mia occurring in the critically ill.1–3 It has been asso-ciated with poor outcomes in most,2–11 but not all,1
studies to date. Consensus on the definition and classifica-
tion of AF has recently been achieved between the American
College of Cardiology, the American Heart Association and
the European Society of Cardiology, and updated European
guidelines were published in 2010.12,13 A new diagnosis of
AF associated with a reversible cause such as acute respira-
tory disease was not included in the consensus classification.
While new-onset AF in a critically ill patient with multior-
gan failure would not be included in this classification, it may
be important to differentiate between a new diagnosis of AF
in the critically ill and those with previously diagnosed AF.
The latter group would now be classified as having paroxys-
mal, persistent, longstanding or permanent AF.
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nurse and incorporated into the case record. All rhythms
other than sinus are confirmed on a printed 12-lead ECG or
review of the paper or electronic rhythm strip by medical staff.
Using programming techniques to query the database, we
used the rhythm documentation to identify the presence and
duration of AF. For the nurse to have documented an
arrhythmia, it would have been present for at least 30 sec-
onds. After identifying patients with AF from the program-
ming query, the accuracy of the cases retrieved was confirmed
by checking for evidence of pertinent treatments or docu-
mentation of the correct diagnosis in the medical records.
A previous diagnosis of paroxysmal or permanent AF was
established on the basis of a prior hospital admission with
documented evidence of AF and confirmation of the
arrhythmia by the patient (if able), a relative or the patient’s
primary-care physician. If these criteria were not met then
the patient was assumed to have AF associated with a crit-
ical illness. The case records and database of patients with
AF were then scrutinised for the following additional data:
past medical history, admitting diagnosis, medication, pres-
ence of vasopressor or inotrope infusion at the time when
AF began and anticoagulants given. Unless contraindicat-
ed, our usual practice is for all patients to receive deep vein
thrombosis prophylaxis (enoxaparin 40 mg/day).
Enoxaparin is not prescribed in the presence of coagulopa-
thy, defined as a prothrombin time international nor-
malised ratio above 1.5, an activated partial thromboplastin
time ratio above 1.5 or fewer than 100 platelets/µL.
The APACHE II is a scoring system used to determine ill-
ness severity in critically ill patients15; it has been validated
in the Scottish population. It is used as a measure of illness
severity in all Scottish ICUs and forms part of our routine
national audit data collection. Patients were excluded from
the analysis if they were not appropriate for APACHE II scor-
ing (e.g., burns, short admission stay, age under 16 years).
This project was submitted to the local ethics committee
(ref. WoS ASD 83); however, the requirement for a formal
review was waived as this was not required under the UK
Governance Arrangements for Research Ethics Committees,
specifically because we only used data obtained as part of
routine clinical care. The corresponding author has full
access to all of the data and is responsible for the integrity of
that data and the accuracy of the data analysis. Where appro-
priate, we analysed the data using medians and interquartile
ranges, chi-square tests and Mann–Whitney U tests.
Logistic regression analyses were also undertaken to eval-
uate the association of AF with death in the ICU adjusting
for age, sex, CRP level and APACHE II score. Patients were
categorised into three groups: no AF, known prior history
of AF and new AF at the onset of critical illness. A total of
78 patients had complete information for all factors con-
sidered in the modelling except for CRP. Multiple imputa-
tion of the 78 missing CRP values was carried out using 10
imputed datasets, thus allowing all 1084 patients in the
dataset to be included in the analysis. The 5% level was used
to determine statistical significance.
RESULTS
A total of 1234 consecutive admissions were identified from
1176 patients (58 readmissions). After excluding patients
with missing APACHE II data (n=92), 1084 complete
records were analysed (Figure 1). A total of 194 of these
patients had AF (17.9%), of which 147 cases (13.6%) were
presumed to be a first diagnosis AF associated with critical
illness, while 47 patients (4.3%) had a documented previ-
ous history of AF. Patients with AF were older and had high-
er APACHE II scores, increased length of ICU unit stay and
higher peak CRP levels (p<0.001) compared with those
without AF (Table 1). Both ICU and hospital mortality rates
were higher in patients with AF (p<0.001).
The cohort of patients with AF was divided into those
with a first diagnosis of AF and those who had a known his-
Table 1. Characteristics of patients with and without AF during their critical illness
Characteristic No AF AF p-value
Patients 890 194 –
ICU mortality 224 (25.2) 79 (40.7) <0.001
Hospital mortality 275 (30.9) 93 (47.9) <0.001
Age, years 53 (39–66) 67 (59–74) <0.001
APACHE II score 18 (13–24) 23 (18–29) <0.001
Predicted hospital mortality, % 27.4 (10.7–51.2) 44.4 (26.2–65.4) <0.001
Length of stay, days 3 (2–7) 7 (3–16) <0.001
C-reactive protein, mg/L 165 (65–263) 256 (152–317) <0.001
Values are n, n (%) or median (interquartile range)
AF = atrial fibrillation; APACHE = Acute Physiology and Chronic Health Evaluation II 
Table 2. Characteristics patients with new-onset and pre-existing AF
Characteristic New-onset AF Prior history of AF p-value
Patients 147 47 –
ICU mortality 67 (45.6) 12 (25.5) 0.015
Hospital mortality 78 (53.1) 15 (31.9) 0.012
Sex, male 91 (61.9) 32 (68.1) 0.44
Age, years 66 (57–73) 71 (62–77) 0.014
APACHE II score 23 (18–29) 24 (18–29) 0.95
Predicted hospital mortality, % 44.4 (26.2–66.5) 46 (26.2–63.7) 0.65
Length of stay, days 8 (3–17) 7 (3–15) 0.191
C-reactive protein, mg/L 268 (166–326) 198 (115–280) 0.012
Values are n, n (%) or median (interquartile range)
AF = atrial fibrillation; APACHE = Acute Physiology and Chronic Health Evaluation II 
Figure 1. Flow chart of patients
demonstrating how the patients
were distributed for analysis.
1234 admissions between 
27/04/2006-05/09/2009 
n=1056 
No AF
n=863
New AF 
n=147 
Prior history of AF
n=46
AF 
n=193 
Exclude readmissions,
patients with missing
data or excluded from
APACHE II scoring
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tory of AF (Table 2). While the two groups were similar in
terms of APACHE II score, predicted hospital mortality and
length of ICU stay, patients with AF associated with a crit-
ical illness were younger (p=0.014) and had higher peak
CRP levels (p=0.012), ICU mortality (p=0.015) and hospi-
tal mortality (p=0.012). The hospital mortality in those with
pre-existing AF was similar to those without AF (31.9% and
30.9%, respectively; p=0.889). 
The comorbid diseases of patients with AF and the drugs
they were taking prior to hospital admission or were admin-
istered during their ICU stay are shown in Table 3. Patients
with previously diagnosed AF were more likely to be on
long-term -blockers, angiotensin-converting enzyme
inhibitors, statins, anticoagulants, digoxin, amiodarone
and diuretics. In addition, they were more likely to be given
a -blocker or digoxin during their critical illness. Patients
with newly diagnosed AF associated with critical illness were
more likely to receive amiodarone and magnesium infu-
sions. There was no significant difference in the use of cat-
echolamine infusions between those with previously
diagnosed AF and AF associated with a critical illness.
Finally, more of the patients with a previous diagnosis of
AF received formal anticoagulation, although more of the
patients with newly diagnosed AF were coagulopathic.
In terms of mortality, 220/224 (98%), 11/12 (92%) and
59/67 (88%) of the deaths in the no AF, prior history of AF
and new-onset AF groups, respectively, occurred within 30
days. This timepoint cut-off was therefore chosen for the
mortality outcome in logistic regression analysis. This pro-
cess assumed that those who were discharged alive from
hospital before 30 days were still alive at 30 days.
At the univariable level, AF category was found to have
an association with death (Table 4). Patients with no AF or
those with a prior history of AF were found to have a lower
risk of death than those with new-onset AF. Age and a high-
er APACHE II score were associated with an increased risk
of death. When the factors were considered together in a
multivariable model, however, only APACHE II score
retained its association with death (Table 4). AF category
and ageing were not found to significantly explain any more
of the variation in deaths than that explained by APACHE
II score. While overall AF only just failed to reach statisti-
cal significance at the 5% level, it was interesting that those
with a history of AF were found to have a 62% (15–83%)
reduction in the risk of death compared with those with AF
at onset (p=0.018). Those with no AF had a 27% reduction
(52% reduction to 11% increase) in the risk of death com-
pared with those with new-onset AF (p=0.137).
DISCUSSION
This study reports on one of the largest cohorts of patients
with AF in a general ICU setting in the literature. As has been
well documented, patients who had AF in the ICU were older
and sicker, and had a longer ICU stay and higher mortality.
Because postmortem examinations are not routinely carried
out in the critically ill, we were unable to establish whether
the patients with AF who died had an increased rate of com-
plications that could be directly attributed to AF. This would
include conditions such as thromboembolism that had not
been clinically recognised.
Previous reports of the consequences of AF in the critical-
ly ill have failed to differentiate between AF that was present
prior to critical illness and new-onset AF associated with crit-
ical illness. From this study, it appears that AF in those with a
prior history of the condition exerts a different response in the
critically ill. These patients had a similar severity of illness, as
determined by APACHE II scores, but lower mortality than
patients with new-onset AF.
Table 3. Demographic and pharmacological data of patients with new-onset AF and 
pre-existing AF
Characteristic New-onset AF, 
n (%)
Prior history of AF,
n (%)
p-value
Comorbid disease
Ischaemic heart disease 47 (32) 30 (63.8) <0.001
Hypertension 59 (40.1) 23 (48.9) 0.29
Diabetes 22 (15) 13 (27.7) 0.049
Chronic respiratory condition 35 (23.8) 9 (19.1) 0.51
Congestive cardiac failure 2 (1.4) 1 (2.1) 0.71
Chronic renal failure 18 (12.2) 5 (10.6) 0.77
Valvular heart disease 2 (1.4) 9 (19.1) <0.001
Other cardiac condition 5 (3.4) 6 (12.8) 0.016
History of malignancy 10 (6.8) 3 (6.4) 0.92
Cerebrovascular disease 12 (8.2) 6 (12.8) 0.34
Peripheral vascular disease 11 (7.5) 6 (12.8) 0.27
Admission drugs
-Blockers 27 (18.4) 26 (55.3) <0.001
ACEI 34 (23.1) 20 (42.6) 0.01
Calcium-channel blocker 31 (21.1) 13 (27.7) 0.36
A2RB 8 (5.4) 6 (12.8) 0.093
Statin 49 (33.3) 27 (57.4) 0.003
Diuretic 36 (24.5) 20 (42.6) 0.018
Aspirin 48 (32.7) 12 (25.5) 0.34
Clopidogrel 4 (2.7) 1 (2.1) 0.82
Nitrates 10 (6.8) 2 (4.3) 0.52
Digoxin 4 (2.7) 18 (38.3) <0.001
Thyroxine 4 (2.7) 4 (8.5) 0.084
Warfarin 3 (2) 28 (59.6) <0.001
Amiodarone 4 (2.7) 4 (8.5) <0.001
Drug therapy for AF 
Magnesium 98 (66.7) 19 (40.4) 0.002
Amiodarone 104 (70.7) 24 (51.1) 0.014
-Blockers 26 (17.7) 20 (42.6) <0.001
Digoxin 13 (9) 18 (38.3) <0.001
Anticoagulation 
DVT prophylaxis (Y/N) 100 (68) 21 (44.7) 0.002
Coagulopathic (Y/N) 72 (49) 12 (25.5) 0.001
Anticoagulated (Y/N) 12 (8) 16 (34) <0.001
Catecholamine infusion 64 (43.5) 17 (36) 0.153
ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; A2RB, angiotensin 2 receptor blocker; DVT = deep vein thrombosis
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On multivariable analysis, the APACHE II score was the
only independent predictor of death. The finding that, over-
all, AF is not an independent predictor of death is similar
to that of the study by Annane et al.1 This may support the
view that AF does not independently contribute to poor
outcomes, but rather that AF associated with critical illness
is a marker of illness severity.
The finding that 13.6% of patients admitted to our unit
developed AF associated with critical illness is in the mid-
range of that reported in other studies.1,2,4,7–9 Support for the
hypothesis that the development of new-onset AF is related
to illness severity comes from the finding that CRP (a mark-
er of inflammation) was significantly higher in those with
AF compared with those without. Interestingly, while there
was no difference in APACHE II scores, the CRP level was
significantly higher in those with new-onset as opposed to
previously diagnosed AF. This supports the hypothesis that
inflammation may play a role in the pathogenesis of AF.16
National and international guidelines regarding rate ver-
sus rhythm control and the use of anticoagulation aim to
reduce the morbidity and mortality associated with AF.12,13,17
Nearly 50% of our patients were on catecholamine infusions
at the onset of AF and therefore using rate-limiting thera-
pies such as -blockers and calcium-channel blockers would
only further compromise the mean arterial pressure. It is also
recommended that anticoagulation be considered to reduce
the risk of stroke in patients with AF; however, a significant
number of our patients were coagulopathic or had absolute
or relative contraindications to formal anticoagulation. It is
also difficult to determine how best to appraise an abnormal
clotting screen in the context of the immobile critically ill
patient who may be prothrombotic. Furthermore, there is a
lack of information regarding the long-term sequelae of AF
associated with a critical illness. Importantly, it is not clear
whether these patients are more likely to develop paroxys-
mal or chronic AF in the future.
The flaws in this study stem from its retrospective nature,
although it is reassuring that the incidence of new AF, preva-
lence of chronic AF and associated increased mortality are
consistent with those reported in current literature.
Although AF is a relatively common arrhythmia in the ICU
population, there is remarkably little literature available to
apply an ‘evidence-based’ approach.
The difference in outcomes between patients with a first
diagnosis of AF associated with critical illness and those with
previously diagnosed AF needs to be confirmed in prospec-
tive studies, but this study does highlight the need to con-
sider these populations separately. The possibility that AF
confers some additional risk cannot be excluded, since the
use of rate-limiting drugs and formal anticoagulation was
more widespread in patients with persistent AF, possibly
off-setting an increased risk from the arrhythmia. 
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Table 4. Death within 30 days: univariable and multivariable logistic regression after
multiple imputation of missing values
Variable Univariable regression Multivariable regression
OR (95% CI) p-value OR (95% CI) p-value
AF category 0.012 0.051
No AF vs new-onset
AF
0.490 
(0.341–0.704)
<0.001 0.728
(0.478–1.107)
0.137
History of AF vs new-
onset AF 
0.456 
(0.215–0.966)
0.040 0.376
(0.167–0.848)
0.018
Male vs female 0.808 
(0.615–1.061)
0.124 0.842
(0.620–1.143)
0.270
Age 1.029 
(1.020–1.038)
<0.001 1.008
(0.998–1.019)
0.107
APACHE II score 1.146 
(1.122–1.170)
<0.001 1.140
(1.116–1.166)
<0.001
C- reactive protein 1.001 
(0.999–1.002)
0.281 0.999
(0.998–1.001)
0.464
AF = atrial fibrillation; APACHE = Acute Physiology and Chronic Health Evaluation II; CI = confidence interval; OR = odds ratio
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